Taigen Biopharmaceuticals Holdings Ltd (4157) — Capital Reinvestment Ratio
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Capital Reinvestment Ratio of 0.05x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$46.51 Million) in capital expenditures (NT$2.24 Million). See Taigen Biopharmaceuticals Holdings Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Taigen Biopharmaceuticals Holdings Ltd Capital Reinvestment Ratio (2021–2025)
This chart tracks Taigen Biopharmaceuticals Holdings Ltd's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd from 2021 to 2025. For live market cap and broader valuation context, see 4157 market cap.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | NT$20.93 Million | NT$4.50 Million | ▼ -39.6% |
| 2023 | 0.36x | NT$20.74 Million | NT$7.39 Million | ▲ +1795.4% |
| 2021 | 0.02x | NT$629.07 Million | NT$11.83 Million | — |